Bajaj Healthcare to Sell Tarapur Business Unit for Up to Rs 4.05 Crore
New Delhi: Bajaj Healthcare Limited has announced that its Board of Directors has approved the sale of one of the company's operational business units located at Plot No. N-178, MIDC, Tarapur Industrial Area, Tarapur, Boisar, Palghar, Maharashtra, for a consideration of up to Rs 4.05 crore, subject to the execution of definitive transaction documents.
The decision was approved through a resolution passed by circulation on June 23, 2026, and disclosed to the BSE Limited and the National Stock Exchange of India Limited (NSE) under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Schedule III and the applicable SEBI Master Circular.
According to the company, the buyer of the operational business unit is Orchem Products. Bajaj Healthcare clarified that the buyer does not belong to the promoter, promoter group or group companies, and the proposed transaction does not qualify as a related party transaction. The company further confirmed that none of its promoters, promoter group entities or group companies has any interest in the buyer or the proposed transaction.
As per the disclosure, the Tarapur unit contributed revenue of Rs 3.31 crore during the last financial year, accounting for 0.54% of the company's total revenue. The unit also contributed net worth of Rs 3.97 crore, representing 0.74% of the company's total net worth.
Bajaj Healthcare stated that the sale consideration will be up to Rs 4.05 crore (Rupees Four Crore and Five Lakh Only) and that the transaction is expected to be completed on or before October 31, 2026. The company informed investors that no agreement for the sale has yet been executed, and therefore the date of execution of the sale agreement is currently not applicable.The filing also clarified that the proposed sale does not fall under a Scheme of Arrangement. Further, the company stated that the sale of the Tarapur unit does not fall within the definition of an "Undertaking" under the Companies Act, 2013, making the provisions of Regulation 37A of the SEBI Listing Regulations inapplicable. The disclosure also noted that the requirements relating to slump sale disclosures are not applicable.
In addition, Bajaj Healthcare informed the stock exchanges that, pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 and the company's Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading in Securities, the trading window has been closed with immediate effect for all directors, designated persons and their immediate relatives. The trading window will remain closed until 48 hours after the formal execution and signing of the definitive agreements relating to the proposed sale.
According to the regulatory filing submitted by Bajaj Healthcare to the BSE and NSE, the proposed divestment of the Tarapur operational business unit is subject to definitive transaction documents, with completion expected by October 31, 2026, while the company has confirmed that the transaction is not a related party transaction and involves an independent buyer.
